Cerecor Inc. is a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. We systematically identify platforms and product candidates for which human proof of concept exists in the intended indication, for either the target or the compound, and for which biomarkers are available to measure therapeutic response. We target conditions where we believe current treatments fail to address unmet medical needs, and where we can apply clinical strategies to increase efficacy signal detection. These strategies include using personalized therapeutic approaches and placebo mitigation techniques to facilitate regulatory approval for our product candidates. Learn More


September 3, 2015

Cerecor Initiates Phase 2 Study for CERC-301, and Antidepressant Product Candidate with Potential for Rapid Onset of Effect

Read More

May 29, 2015

Cerecor Announces Updates to Management Team and Board of Directors

Read More